Home health remedies Competitive Intelligence Gets a Boost with Reaxys Patent Expansion

Competitive Intelligence Gets a Boost with Reaxys Patent Expansion

8
0
SHARE

Posted on April 30th, 2021 by in Chemistry

The insights only found in patents can provide a crucial
competitive advantage for innovative companies. In response to customer demand,
Elsevier recently announced a major expansion of the patent content available
to users of Reaxys, our chemistry information solution. Users can now get relevant
patents for pharma and chemical R&D from 105 patent offices and 170 IPC classes.
This also includes English language translations of foreign-language patents,
which is important given that scientific advances are being made every day all
across the globe.

The expansion comes as a result of a collaboration between
Elsevier and LexisNexis that offers Reaxys customers access to the LexisNexis
Intellectual Property patent content behind LexisNexis TotalPatent One.

We talked to Rosalind Sankey, Senior Product Manager Chemistry at
Elsevier, to find out more about how Reaxys users can benefit from this new
offering.

What does Elsevier’s partnership with LexisNexis bring to Reaxys
users?

Rosalind Sankey: They give us expanded content and credibility, which gives our Reaxys community confidence that the content they’re getting is good quality. It’s exhaustive and probably the most expansive available in the world. The other thing that’s provided through LexisNexis, which other solutions don’t appear to provide, is the translation of the patent claim and the abstract, which we’ve already heard from customer feedback is quite important. It makes it easier to search for text.

What kind of unique insights can chemistry researchers and
information specialists get from patents in Reaxys that they can’t find
elsewhere?

RS: Because we’ve gone from seven patent offices to the whole 105
offices, and we have done so with a sophisticated automated pipeline, we have
the potential to deliver more authorities than other chemistry-based solution in
really short times — gaining breadth of content in a timely manner. What’s
pretty unique with our solution is the way we are using data science to identify
and extract critical information from patents; it’s really quite novel and to
do it well requires state-of-the art technology. From an end user point of
view, it’s about the fact that we can get comprehensive information to them really
quickly.

We still index a subset of those patents with manual excerption, so
customers are benefiting from our unique excerpted experimental information,
giving them deep insights into the innovations published in patents. The new
automated pipeline delivers high breadth of content, while the manual
excerption goes deep. So customers can access biological activities, substance properties,
and in-depth information which you can’t get in other solutions.

So it’s a unique combination that offers the breadth of coverage and fast retrieval time to the customer with the automated pipeline AND the in-depth insights with a manual pipeline?

RS: Exactly. Our competitors did that breadth piece well, which is where we have stepped up with more patent coverage. But they don’t necessarily have the depth that we do.

How much do researchers working in pharmaceutical R&D, in
particular, benefit from this increased access to patent information?

RS: When you’re doing competitive intelligence searching, it tends
to be text-based searching – looking at what competitor companies are working
on, biological targets, indications and diseases. This is where the biggest
step forward is with this expansion. You can do that text-based searching on
competitive intelligence in Reaxys and be confident you’re covering more of the
patent landscape.

We can already see from the customer feedback that they’re saying,
‘Now I’m going to start using Reaxys as my first choice to look for this
information.’

How is target searching on Reaxys different now than previously?

RS: When you searched for a target in Reaxys before, it was all about the bioactivity data related to that patent or that compound that was tested against. Which is great when you want to go in-depth. But when you’re talking about that competitive intelligence part, it’s not so much the data that you’re interested in. When you’re doing competitive intelligence, the question is: ‘I have this target that I’m about to start a project on. What is known about it and who else is working on it? Have I got a good chance of building a project that’s going to be successful looking for compounds against this target or not?’

Rosalind Sankey, Senior Product Manager Chemistry at Elsevier

Previously, it was too narrow, covering too few offices. We have
not only expanded the coverage, but also ensured to apply the latest data
science technology to assess the relevancy of a given target. The reason this
is so important is you’re adding the ability to do higher-level, broader
text-based searching on biological targets, retrieving relevant results thanks
to our primary target indexing. Once you have a good view of the patent
landscape, you can decide for which targets you want to retrieve in-depth
experimental data.

If you can’t do that high-level target search on a text basis in
patent or journal content, you’ve only seen a very narrow world. Later on in
your project, you’re going to say, ‘Okay, so which substances have
bioactivities against this target?’ That’s also great where the manual excerption
in Reaxys comes in, but you need both. You can’t have just one or the other.

Q: Can you share a little bit about how this would have helped you
in your own practice when you were doing research?

RS: Definitely. We’d worked with a CRO, and we’d often be bidding
for projects and creating proposals. This would have helped me because when you
are trying to understand the patent landscape and setting out the vision for
the project, that’s where this type of information is crucial. I would have
been able to use Reaxys to investigate – ‘Is that a good strategy to pursue?
Does that disease have a causal link with that target? Is there a good
opportunity to pursue this or not?’ And also seeing who else is playing in that
space as well.

What it allows you to do is craft those proposals with a lot of
scientific information, so you’ve got a better chance to win the business. And
then you also have a better opportunity to execute on the project, because when
you’re executing, Reaxys experimental data is critical to find insights quickly
and progress your project with confidence on the choices you make – so that’s where
the manual excerption is important.

Are there any other projects you are working on with LexisNexis?

RS: Yes. Another piece of critical feedback we’ve had from customers
is that they want stronger data and information on the patent ownership,
because sometimes patents can move if companies get acquired, or sometimes
companies buy patents from other companies.

This is a strength for LexisNexis. They track the movement of
patent ownership and company information really, really well. What we’re
working on with them on right now is how do we get that information into
Reaxys, so users can easily search for ownership of a patent.

On the other side is allowing users to see who filed the patent originally, and who owns it now, because it can change. That was another piece of strong customer feedback we received, not only that the search perspective needed to improve and the filtering by having more structured company name information, but also the status of a patent as well.

Learn more about the extensive chemistry patent coverage available in Reaxys here.

Please enable JavaScript to view the comments powered by Disqus.

R&D Solutions for Pharma & Life Sciences

We’re happy to discuss your needs and show you how Elsevier’s Solution can help.

Contact Sales

!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘533182150132648’);
fbq(‘track’, “PageView”);
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘1737613393127776’,
{ em: ‘insert_email_variable,’ }
);
fbq(‘track’, ‘PageView’);

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

4 × four =